In a trial, Loomba et al. [56] evaluated if the antisense inhibition of diacylglycerol O-acyltransferase 2 (DGAT2) could effectively reduce liver fatting in individuals with diabetes and NAFLD and showed that the inhibition reduced liver fat content without causing hyperlipidemia. The gene discussed is DGAT2; the disease is diabetes mellitus.